News & Events

• April 22, 2021
  

  C-Path Opens Access to Duchenne Regulatory Science Consortium Database

  Database will allow sharing of individual-level data with the goal of accelerating therapy development for Duchenne muscular dystrophy TUCSON, Ariz., April 22, 2021 — Critical Path Institute (C-Path) announced today that it will open access to the Duchenne Regulatory Science Consortium (D-RSC) database to qualified researchers, through its Rare Disease Cures Accelerator, Data and Analytics...
• April 22, 2021
  

  Data Collaboration Center Request for Proposal

  RFP: The RDCA Branding & Web Portal Data Collaboration Center’s (DCC’s) platform development team is seeking a proposal, including timelines and budget, to build a user portal for our rare disease data sharing platform – Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP).   RFP: RDCA Branding & Web Portal
• February 17, 2021
  

  C-Path’s Data Collaboration Center Seeks Proposals

  The Critical Path Institute Data Collaboration Center is seeking proposals for the creation of non-identifiable, synthetic patient-level EHR datasets. The proposal submission deadline is February 26, 2021. Please send any questions you have about the RFP to Amanda J. Borens, MS, Executive Director of Data Science, aborens@c-path.org by February 19, 2021. Include “EHR RFP” in the subject line.

• December 3, 2020
  

  C-Path Selects Aridhia to Support Rare Disease Cures Accelerator-Data and Analytics Platform

    TUCSON, Ariz., December 3, 2020 — The Critical Path Institute (C-Path) today announced it has selected Aridhia to support its Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP). The RDCA-DAP initiative, launched in September 2019 as a collaborative project between C-Path and the National Organization for Rare Disorders® (NORD), will provide a centralized and...
• October 28, 2020
  

  C-Path and EATRIS To Collaborate on RDCA-DAP

  C-Path has signed a Memorandum of Understanding with EATRIS, the European infrastructure for translational medicine, to accelerate drug development for rare diseases by increasing the efficiency of translation of potential therapeutics through preclinical and clinical development …